On 14 December 2018, orphan designation (EU/3/18/2118) was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.
Treatment of Hutchinson-Gilford progeria
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
Zokinvy : Orphan maintenance assessment report (initial authorisation) (PDF/214.95 KB)
First published: 01/08/2022
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: